Loading...
Anaplastic thyroid carcinoma is notorious for its aggressiveness, with the BRAF V600E mutation driving approximately 40% of cases. The FDA has approved the combination of the BRAF inhibitor dabrafenib with the MEK inhibitor trametinib (DT) for patients with this disease. Despite the combination's overall response rate (ORR) of 69%, updated analyses reveal an ORR of 56% and a median overall survival (OS) of 14.5 months (Nature Med 2023: 29:1103), indicating limited long-term benefits. To investigate whether adding an immune checkpoint inhibitor enhances the durability of response, researchers retrospectively examined the effect of pembrolizumab.
In the dataset, 23 patients with anaplastic thyroid carcinoma were treated with DT, and 48 receive…